CEM/C2细胞
年限： 4 years
ATCC Number： CRL-2264™
相关**： 白血病
数量： 大量
生长状态： 悬浮生长
器官来源： 外周血
运输方式： 冻存运输
细胞类型： T**细胞
细胞形态： **样
是否是肿瘤细胞： 0
物种来源： 人
CEM/C2细胞Designations: CEM/C2
Depositors: WG Harker
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens
Morphology: lymphoblast
Source: Organ: peripheral blood
Disease: acute lymphoblastic leukemia
Cell Type: T lymphoblast;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
DNA Profile (STR): Amelogenin: X
CSF1PO: 11
D13S317: 11,12
D16S539: 10,13
D5S818: 13
CEM/C2细胞D7S820: 9,8.3
THO1: 6,7
TPOX: 8
vWA: 17,19
Age: 4 years
Gender: female
Ethnicity: Caucasian
Comments: CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119).
The cell line was selected and subcloned in 1991 for resistance to CPT.
The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells.
CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.
CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine.
CEM/C2 cells display atypical multidrug resistance (MDR), altered topoisomerase I catalytic activity and a unique topoisomerase I mutation (Asn722Ser).
Resistance to CPT is stable for up to six months.
Propagation: CEM/C2细胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Doubling Time: 30 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC CCL-119
References: 22339: Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731
23117: Fujimori A, et al. CEM/C2细胞Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333
